Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators and co-ordinators. Komajda M, et al. Among authors: hildebrandt p. Eur J Heart Fail. 2004 Jun;6(4):467-75. doi: 10.1016/j.ejheart.2003.12.019. Eur J Heart Fail. 2004. PMID: 15182773 Free article. Clinical Trial.
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL.
Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P, Parrinello G, Robertson M, Steg PG, Tendera M, Ford I, Fox K, Ferrari R; BEAUTIFUL Echo-BNP Investigators. Ceconi C, et al. Among authors: hildebrandt p. Int J Cardiol. 2011 Feb 3;146(3):408-14. doi: 10.1016/j.ijcard.2010.10.125. Epub 2010 Nov 26. Int J Cardiol. 2011. PMID: 21112101 Clinical Trial.
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, Soler-Soler J, Scherhag A, Lutiger B, Rydén L. Remme WJ, et al. Among authors: hildebrandt p. Cardiovasc Drugs Ther. 2004 Jan;18(1):57-66. doi: 10.1023/B:CARD.0000025756.32499.6f. Cardiovasc Drugs Ther. 2004. PMID: 15115904 Clinical Trial.
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; CLARICOR Trial Group. Kastrup J, et al. Among authors: hildebrandt p. Eur Heart J. 2009 May;30(9):1066-72. doi: 10.1093/eurheartj/ehp049. Epub 2009 Mar 6. Eur Heart J. 2009. PMID: 19270316 Free article. Clinical Trial.
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Iversen KK, Teisner B, Winkel P, Gluud C, Kjøller E, Kolmos HJ, Hildebrandt PR, Hilden J, Kastrup J; CLARICOR Trial Group. Iversen KK, et al. Among authors: hildebrandt pr. Atherosclerosis. 2011 Jan;214(1):203-8. doi: 10.1016/j.atherosclerosis.2010.10.025. Epub 2010 Nov 3. Atherosclerosis. 2011. PMID: 21093861 Clinical Trial.
629 results